APON(SZ:300753)2020-04-23 16:00Financial Performance - Total revenue for Q1 2020 was ¥37,146,726.16, a decrease of 46.67% compared to ¥69,655,092.77 in the same period last year[8] - Net profit attributable to shareholders was ¥8,872,599.72, down 41.82% from ¥15,250,873.36 year-on-year[8] - Net profit after deducting non-recurring gains and losses was ¥3,827,824.95, a significant decline of 72.46% compared to ¥13,899,130.35 in the previous year[8] - Basic and diluted earnings per share were both ¥0.11, down 42.11% from ¥0.19 in the previous year[8] - Total operating revenue for Q1 2020 was CNY 37,146,726.16, a decrease of 46.3% compared to CNY 69,655,092.77 in Q1 2019[37] - Net profit for Q1 2020 was CNY 8,872,599.72, down 42.3% from CNY 15,336,376.79 in Q1 2019[39] - Total profit for Q1 2020 was CNY 11,690,862.53, down 35.5% from CNY 18,110,593.14 in Q1 2019[39] Cash Flow - The net cash flow from operating activities was -¥23,073,185.78, worsening by 49.58% from -¥15,424,999.55 in the same period last year[8] - Cash inflow from operating activities was CNY 53,867,919.21, a decrease of 17.7% compared to CNY 65,421,482.02 in the same period last year[43] - The total cash outflow from investing activities was ¥61,288,011.24, significantly higher than ¥420,983,266.77 in the previous year, resulting in a net cash flow from investing activities of -¥29,134,619.46[44] - The company experienced a net decrease in cash and cash equivalents of -¥52,207,805.24 in Q1 2020, compared to -¥367,268,847.17 in the same period last year[45] - Cash and cash equivalents at the end of Q1 2020 stood at ¥368,432,661.91, down from ¥436,837,220.68 at the beginning of the quarter[45] Assets and Liabilities - Total assets at the end of the reporting period were ¥735,399,937.81, a decrease of 2.94% from ¥757,642,068.05 at the end of the previous year[8] - Total liabilities decreased to CNY 51,645,913.13 from CNY 82,760,643.09, reflecting a reduction of 37.6%[31] - Current liabilities totaled CNY 49,139,856.01, a significant drop from CNY 80,268,318.11 in the previous period[31] - The total current assets as of March 31, 2020, amounted to 509.02 million RMB, down from 539.48 million RMB at the end of 2019, a decrease of approximately 5.6%[29] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,099[11] - The largest shareholder, Wang Ningyu, holds 36.15% of the shares, with 5,000,000 shares pledged[11] - Net assets attributable to shareholders increased by 1.31% to ¥683,754,024.68 from ¥674,881,424.96 at the end of the previous year[8] Operational Challenges - The company faced operational challenges due to the COVID-19 pandemic, delaying the resumption of work until February 17, 2020[17] - The marketing network construction project was not implemented as planned due to changes in market and policy environments post-IPO[22] Investments and Future Plans - The company is actively preparing to establish a business platform and set up an angel fund to enhance its service capabilities in the medical device sector[18] - The total amount of committed investment projects is 26,293 million RMB, with a cumulative benefit of 4,286.35 million RMB[22] - The company plans to use idle funds of up to 230 million RMB for cash management, ensuring no impact on normal operations[23] Research and Development - Research and development expenses for Q1 2020 were CNY 4,272,535.29, down 15.2% from CNY 5,038,018.66 in Q1 2019[40] - Jiangsu Aipeng Medical Technology Co., Ltd. is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[48] Compliance and Standards - The company has not reported any non-operating fund occupation by controlling shareholders during the reporting period[25] - The company has not experienced any violations regarding external guarantees during the reporting period[24] - The company implemented new revenue and lease standards starting in 2020, affecting prior comparative data[57]